Skip to content

D&A at other companies

Amgen logo
AmgenAMGN
$1.12B-19.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$102K-20.3%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$891K-4.8%
Savara logo
SavaraSVRA
$24K-20.0%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$130K-11.0%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s D&A?
Upstream Bio, Inc. (UPB) reported D&A of $49K in Q1 2026.
How has Upstream Bio, Inc.'s D&A changed year-over-year?
Upstream Bio, Inc.'s D&A increased by 14.0% year-over-year, from $43K to $49K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.